BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 31839169)

  • 21. Effectiveness of Adjuvant Ovarian Function Suppression in Premenopausal Women With Early Breast Cancer: A Multicenter Cohort Study.
    Ferreira AR; Ribeiro J; Miranda A; Mayer A; Passos-Coelho JL; Brito M; Fernandes J; Gouveia J; Costa L; Vaz-Luis I
    Clin Breast Cancer; 2019 Oct; 19(5):e654-e667. PubMed ID: 31327728
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients.
    Del Mastro L; Rossi G; Lambertini M; Poggio F; Pronzato P
    Cancer Treat Rev; 2016 Jan; 42():18-23. PubMed ID: 26613834
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer.
    Lambertini M; Del Mastro L; Viglietti G; Pondé NF; Solinas C; de Azambuja E
    Curr Treat Options Oncol; 2017 Jan; 18(1):4. PubMed ID: 28185173
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Goel S; Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004562. PubMed ID: 19821328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Triptorelin: A Review of its Use as an Adjuvant Anticancer Therapy in Early Breast Cancer.
    Frampton JE
    Drugs; 2017 Dec; 77(18):2037-2048. PubMed ID: 29177573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.
    Ribi K; Luo W; Bernhard J; Francis PA; Burstein HJ; Ciruelos E; Bellet M; Pavesi L; Lluch A; Visini M; Parmar V; Tondini C; Kerbrat P; Perelló A; Neven P; Torres R; Lombardi D; Puglisi F; Karlsson P; Ruhstaller T; Colleoni M; Coates AS; Goldhirsch A; Price KN; Gelber RD; Regan MM; Fleming GF
    J Clin Oncol; 2016 May; 34(14):1601-10. PubMed ID: 27022111
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The aromatase inhibitors (plus ovarian function suppression) in premenopausal breast cancer patients: ready for prime time?
    Montagna E; Cancello G; Colleoni M
    Cancer Treat Rev; 2013 Dec; 39(8):886-90. PubMed ID: 23725877
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM).
    Gori S; Puglisi F; Cinquini M; Pappagallo G; Frassoldati A; Biganzoli L; Cortesi L; Fiorentino A; Angiolini C; Tinterri C; De Censi A; Levaggi A; Del Mastro L
    Eur J Cancer; 2018 Aug; 99():9-19. PubMed ID: 29886394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. OFS plus AI or SERM vs. SERM alone in premenopausal women with hormone receptor-positive breast cancer: a prospective cohort study using the real-world database.
    Hu K; He P; Peng Q; Zhong X; Deng L; Xie Y; Li J; Xu H; Lu D; Zheng H
    Breast Cancer; 2019 May; 26(3):339-348. PubMed ID: 30367358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
    Regan MM; Pagani O; Francis PA; Fleming GF; Walley BA; Kammler R; Dell'Orto P; Russo L; Szőke J; Doimi F; Villani L; Pizzolitto S; Öhlschlegel C; Sessa F; Peg Cámara V; Rodríguez Peralto JL; MacGrogan G; Colleoni M; Goldhirsch A; Price KN; Coates AS; Gelber RD; Viale G;
    Breast Cancer Res Treat; 2015 Nov; 154(2):275-86. PubMed ID: 26493064
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT.
    Regan MM; Walley BA; Francis PA; Fleming GF; Láng I; Gómez HL; Colleoni M; Tondini C; Pinotti G; Salim M; Spazzapan S; Parmar V; Ruhstaller T; Abdi EA; Gelber RD; Coates AS; Goldhirsch A; Pagani O
    Ann Oncol; 2017 Sep; 28(9):2225-2232. PubMed ID: 28911092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extended endocrine therapy in premenopausal breast cancer patients: Where are we now?
    Villasco A; D'Alonzo M
    Breast J; 2020 Oct; 26(10):2018-2020. PubMed ID: 32468640
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant ovarian function suppression and tamoxifen in premenopausal breast cancer patients: A meta-analysis.
    Azim HA; Shohdy KS; Kaldas DF; Kassem L; Azim HA
    Curr Probl Cancer; 2020 Dec; 44(6):100592. PubMed ID: 32527567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer.
    Chlebowski RT; Pan K; Col NF
    Breast Cancer Res Treat; 2017 Jan; 161(2):185-190. PubMed ID: 27785653
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial.
    Perrone F; De Laurentiis M; De Placido S; Orditura M; Cinieri S; Riccardi F; Ribecco AS; Putzu C; Del Mastro L; Rossi E; Tinessa V; Mosconi AM; Nuzzo F; Di Rella F; Gravina A; Iodice G; Landi G; Pacilio C; Forestieri V; Lauria R; Fabbri A; Ibrahim T; De Maio E; Barni S; Gori S; Simeon V; Arenare L; Daniele G; Piccirillo MC; Normanno N; de Matteis A; Gallo C
    Eur J Cancer; 2019 Sep; 118():178-186. PubMed ID: 31164265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
    Jankowitz RC; McGuire KP; Davidson NE
    Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Picking the optimal endocrine adjuvant treatment for pre-menopausal women.
    Colleoni M; Munzone E
    Breast; 2015 Nov; 24 Suppl 2():S11-4. PubMed ID: 26249119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aromatase inhibitor plus ovarian suppression as adjuvant therapy in premenopausal women with breast cancer.
    Figg WD; Cook K; Clarke R
    Cancer Biol Ther; 2014; 15(12):1586-7. PubMed ID: 25535893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group.
    Tevaarwerk AJ; Wang M; Zhao F; Fetting JH; Cella D; Wagner LI; Martino S; Ingle JN; Sparano JA; Solin LJ; Wood WC; Robert NJ
    J Clin Oncol; 2014 Dec; 32(35):3948-58. PubMed ID: 25349302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.